Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2020-03-24 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
108年第4季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial tables showing changes in equity, including items such as common stock capital, capital surplus, legal surplus reserve, special surplus reserve, undistributed earnings, retained earnings, foreign currency translation adjustments, treasury stock, and total equity attributable to the parent company and non-controlling interests. The data covers two fiscal periods (current and prior year) and includes detailed accounting line items and amounts in thousands of New Taiwan Dollars. The document is titled as a consolidated equity changes statement, which is a component of comprehensive financial reporting. The length of the document is 4328 characters, which is relatively short but contains substantive financial data rather than just an announcement or a certification. This type of detailed financial statement is typically part of an Interim/Quarterly Report or Annual Report. However, since the document is focused on equity changes and does not include a full set of financial statements or comprehensive annual disclosures, it aligns best with an Interim / Quarterly Report (IR) classification, which includes substantive financial data for a period shorter than a full fiscal year or partial financial statements. There is no indication that this is an announcement or a certification, so it is not RPA or RNS. Therefore, the most appropriate classification is IR with high confidence. FY 2019
2020-03-24 Chinese
108年度應收帳款周轉率
Fund Information / Factsheet Classification · 90% confidence The document is very short (288 characters) and contains financial ratios related to accounts receivable turnover and average collection days for two fiscal years (107 and 108). It includes a brief explanation for a significant change in the turnover ratio. There is no indication of a full financial report, audit, or management discussion. The content resembles a brief financial fact summary or a short disclosure rather than a comprehensive report. Given the brevity and nature of the data, it fits best as a Fund Information / Factsheet (FS) or a brief financial summary. Since it is from a listed company and provides key financial metrics with explanation, FS is the most appropriate classification. Confidence is high due to clear financial metric presentation and explanatory note.
2020-03-24 Chinese
108年度毛利率
Fund Information / Factsheet Classification · 90% confidence The document contains a brief financial summary table showing annual revenue, cost, gross profit, and gross margin percentages for two years (107 and 108, likely referring to fiscal years in a non-Gregorian calendar). The text mentions an update date (April 1) and a note about explaining significant changes in gross margin. The document is very short (378 characters) and does not contain detailed financial statements or analysis. It appears to be a brief financial factsheet or summary rather than a full report or announcement. Given the brevity and content, it fits best as a Fund Information / Factsheet (FS) which typically provides a short summary of key financial data.
2020-03-24 Chinese
109年2月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 科妍 for the period 民國109年02月 (February 2020). It includes comparative figures from the previous year and percentage changes. The document is very short (766 characters) and contains no detailed financial statements, management discussion, or comprehensive analysis. It appears to be a regulatory disclosure of revenue figures rather than a full financial report or earnings release. There is no indication of a conference call transcript, AGM materials, or audit information. The document is a regulatory announcement of financial data, likely a routine revenue report submitted to a regulatory body. Given the short length and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full Interim Report or Earnings Release.
2020-03-10 Chinese
109年2月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 科妍, providing information about fund lending balances and endorsement guarantees for the current and previous months, with all values being zero. The content is very short (601 characters) and consists mainly of tabular data about financial guarantees and lending, without any detailed financial statements, management discussion, or regulatory certifications. It does not contain any narrative or comprehensive financial report. Given the short length and nature of the data, this is a regulatory disclosure or announcement rather than a full report. It fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-03-10 Chinese
109年02月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, supervisors, managers, and their family members. It shows changes in shareholdings, types of shares held, and other related insider information. There is no indication of financial statements, earnings data, or report publication announcements. The content is focused on insider share transactions and holdings, which aligns with the definition of Director's Dealing (DIRS). The document length is sufficient and the content is substantive insider shareholding data, not a mere announcement or certification.
2020-03-03 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.